| Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery. | |
| | |
MedLine Citation:
|
PMID: 15163286 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
With stenting, restenosis occurs in approximately 25% of patients and the incidence is even higher in patients with diabetes, small coronary vessels and long lesions. The sirolimus-eluting balloon-expandable stent in the treatment of patients with de novo native coronary-artery lesions (SIRIUS) trial, enrolled patients with more challenging conditions, including a higher frequency of diabetes, more complex lesion morphology and longer lesions and showed benefits in all groups. After 240 days, the frequency of stenosis of at least 50% of the luminal diameter was 3.2 and 35.4% in the sirolimus and standard stents groups, respectively. The TAXUS-IV trial was the first large-scale trial on the safety and efficacy of paclitaxel-eluting stents in a broad population of patients and lesions, and established the safety and effectiveness of this agent. After 9 months, there was a mean stenosis of 17% in the paclitaxel group compared to 37% of patients treated with a bare stent. Thus, the local delivery of potent cell cycle inhibitors (sirolimus, paclitaxel) from stents being used for revascularisation dramatically decreases the incidence of restenosis in the populations of patients studied so far and represents a major advancement in the treatment of coronary artery disease. |
| | |
Authors:
|
Sheila A Doggrell |
Related Documents
:
|
9468206 - 'optimal' directional coronary atherectomy: final results of the optimal atherectomy re... 16791596 - Intracoronary beta-brachytherapy using a rhenium-188 filled balloon catheter in resteno... 17413036 - Low levels of nogo-b in human carotid atherosclerotic plaques are associated with an at... 17107366 - Complex coronary interventions: unprotected left main and bifurcation lesions. 16161076 - Endovascular interventional mri. 9259986 - Comparative analysis of apo(a) gene alleles: distribution of pentanucleotide repeats in... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 5 ISSN: 1465-6566 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2004 Jun |
Date Detail:
|
Created Date: 2004-05-27 Completed Date: 2004-10-21 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 1431-4 Citation Subset: IM |
Affiliation:
|
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s_doggrell@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Balloon
/
methods Clinical Trials as Topic Coronary Restenosis / prevention & control* Humans Immunosuppressive Agents / therapeutic use* Paclitaxel / therapeutic use* Sirolimus / therapeutic use* Stents* |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a revie...
Next Document: Alterations in colonic barrier function caused by a low sodium diet or ionizing radiation.